These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 9193348)
21. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Xiao J; Horst S; Hinkle G; Cao X; Kocak E; Fang J; Young D; Khazaeli M; Agnese D; Sun D; Martin E Cancer Biother Radiopharm; 2005 Feb; 20(1):16-26. PubMed ID: 15778575 [TBL] [Abstract][Full Text] [Related]
22. A novel monoclonal antibody design for radioimmunotherapy. Forero A; Meredith RF; Khazaeli MB; Carpenter DM; Shen S; Thornton J; Schlom J; LoBuglio AF Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823 [TBL] [Abstract][Full Text] [Related]
23. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Murray JL; Macey DJ; Grant EJ; Rosenblum MG; Kasi LP; Zhang HZ; Katz RL; Riger PT; LeBherz D; Bhadkamkar V Cancer Res; 1995 Dec; 55(23 Suppl):5925s-5928s. PubMed ID: 7493372 [TBL] [Abstract][Full Text] [Related]
29. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364 [TBL] [Abstract][Full Text] [Related]
30. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219 [TBL] [Abstract][Full Text] [Related]
31. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Meredith R; Shen S; Macey D; Khazaeli MB; Carey D; Robert F; LoBuglio A Cancer Biother Radiopharm; 2003 Jun; 18(3):393-404. PubMed ID: 12954125 [TBL] [Abstract][Full Text] [Related]
32. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053 [TBL] [Abstract][Full Text] [Related]
33. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195 [TBL] [Abstract][Full Text] [Related]
34. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752 [TBL] [Abstract][Full Text] [Related]
35. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. Shen S; Forero A; Meredith RF; LoBuglio AF Cancer Biother Radiopharm; 2011 Feb; 26(1):127-33. PubMed ID: 21355784 [TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303 [TBL] [Abstract][Full Text] [Related]
37. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330 [TBL] [Abstract][Full Text] [Related]
38. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. Scheinberg DA; Straus DJ; Yeh SD; Divgi C; Garin-Chesa P; Graham M; Pentlow K; Coit D; Oettgen HF; Old LJ J Clin Oncol; 1990 May; 8(5):792-803. PubMed ID: 2332769 [TBL] [Abstract][Full Text] [Related]
39. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Meredith RF; Khazaeli MB; Plott WE; Grizzle WE; Liu T; Schlom J; Russell CD; Wheeler RH; LoBuglio AF Clin Cancer Res; 1996 Nov; 2(11):1811-8. PubMed ID: 9816134 [TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Richman CM; DeNardo SJ; O'Grady LF; DeNardo GL Cancer Res; 1995 Dec; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]